Abstract
New uniform response criteria are required to adequately assess clinical outcomes in myeloma. The European Group for Blood and Bone Marrow Transplant/International Bone Marrow Transplant Registry criteria have been expanded, clarified and updated to provide a new comprehensive evaluation system. Categories for stringent complete response and very good partial response are added. The serum free light-chain assay is included to allow evaluation of patients with oligo-secretory disease. Inconsistencies in prior criteria are clarified making confirmation of response and disease progression easier to perform. Emphasis is placed upon time to event and duration of response as critical end points. The requirements necessary to use overall survival duration as the ultimate end point are discussed. It is anticipated that the International Response Criteria for multiple myeloma will be widely used in future clinical trials of myeloma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Durie BGM . New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals . Clin Lymphoma Myeloma 2005 ; 6 : 181 – 190 .
Rajkumar SV, Dispenzieri A . Evaluation and monitoring of response to therapy in multiple myeloma . Haematologica 2005 ; 90 : 1305 – 1308 .
Child JA, Morgan G, Davies F, Owen RG, Bell SE, Hawkins K et al . High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma . N Engl J Med 2003 ; 348 : 1875 – 1883 .
Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al . Single versus double autologous stem-cell transplantation for multiple myeloma . N Engl J Med 2003 ; 26 : 2495 – 2502 .
Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al . Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation . Br J Haematol 1998 ; 102 : 1115 – 1123 .
Durie BGM, Jacobson J, Barlogie B, Crowley J . Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials . J Clin Oncol 2004 ; 22 : 1857 – 1863 .
Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR et al . POEMS syndrome: definitions and long-term outcome . Blood 2003 ; 101 : 2496 – 2506 .
International Myeloma Working Group . Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group . Br J Haematol 2003 ; 121 : 749 – 757 .
Greipp PR, San Miguel J, Durie BGM, Crowley J, Barlogie B, Blade J et al . International staging system for multiple myeloma . J Clin Oncol 2005 ; 23 : 3412 – 3420 .
Durie BGM . Staging and kinetics in multiple myeloma . In: Salmon SE (ed). Clinics in Haematology: Myeloma and Related Disorders, Vol. 2, Number 1, WB Saunders Company, Ltd: Alden Press, Ocford, 1982, pp 3 – 18 .
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al . A phase II study of bortezomib in relapsed, refractory myeloma . N Engl J Med 2003 ; 348 : 2609 – 2617 .
Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M et al . PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma . Br J Haematol 2005 ; 129 : 755 – 762 .
Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR . Serum free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma . Blood 2001 ; 97 : 2900 – 2902 .
Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT . Serum testing for assessment of patients with Bence–Jones myeloma . Lancet 2003 ; 361 : 489 – 491 .
Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child A, Bradwell AR . Serum free light chains for monitoring multiple myeloma . Br J Haematol 2004 ; 126 : 348 – 354 .
Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T et al . Doxorubicin and dexmaethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma . Br J Hematol 2006 ; 132 : 155 .
Rajkumar SV, Kyle RA, Therneau TM, Melton III LJ, Bradwell AR, Clark RJ et al . Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance . Blood 2005 ; 106 : 812 – 817 .
Kyle RA, Schreiman JS, McLeod RA, Beabout JW . Computed tomography in diagnosis and management of multiple myeloma and its variants . Arch Int Med 1985 ; 145 : 1451 – 1452 .
Durie BGM, Waxman AD, D'Angeloa A, William CM . Whole body F-FDG18 PET identifies high-risk myeloma . J Nucl Med 2002 ; 43 : 1457 – 1463 .
Durie BGM . Is magnitude of initial response predictive for survival in multiple myeloma? Ann Oncol 1999 ; 2 : 166 – 169 .
Lahuerta JJ, Martinez-Lopez J, de la Serna J, Blade J, Grande C, Alegra A et al . Remission status defined by immunofixation versus electrophoresis following autologus transplantation has a major impact on the outcome of multiple myeloma patients . Br J Haematol 2000 ; 109 : 438 – 446 .
Riccardi A, Mora O, Tinelli C, Porta C, Danova M, Brugnatelli S et al . Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomized protocol . Eur J Cancer 2003 ; 39 : 31 – 37 .
Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al . Superiority of thalidomide and dexamethasone over vincristine–doxorubicin–dexmaethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma . Blood 2005 ; 106 : 359 .
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer E, Facon T et al . Bortezomib or high-dose dexamethasone for relapsed multiple myeloma . N Engl J Med 2005 ; 352 : 2487 – 2498 .
Rajkumar SV, Dispenzieri A . Evaluation and monitoring of response to therapy in multiple myeloma . Haematologica 2005 ; 90 : 1305 – 1308 .
Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al . Standard chemotherapy compared with high dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup trial S9321 . J Clin Oncol 2006 ; 24 : 929 – 936 .
Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al . Thalidomide and hematopoietic-cell transplantation for multiple myeloma . N Engl J Med 2006 ; 354 : 1021 – 1030 .
Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al . Oral melphalan and prednisone therapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: a randomized controlled trial . Lancet 2006 ; 367 : 825 – 831 .
Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al . Impact of complete remission with intensive therapy in patients with responsive multiple myeloma . Bone Marrow Transplant 2001 ; 27 : 1037 – 1043 .
Author information
Authors and Affiliations
Consortia
Corresponding authors
Additional information
Please see Corrigendum. The PDF and HTML versions of this article remain uncorrected.
Please click on the abstract or full text for the link to the corrigendum attached to this article. Please note the article and PDF have not been corrected.
Appendix A.
Appendix A.
International myeloma working group:
Raymond Alexanian, MD Anderson, Houston, Texas
Kenneth Anderson, DFCI, Boston, Massachusetts
Michael Attal, Purpan Hospital, Toulouse, France
Herve Avet-Loiseau, Institute de Biologie, Nantes, France
Leif Bergsagel, Mayo Clinic Scottsdale
Joan Bladé, Hospital Clinica, Barcelona, Spain
Bart Barlogie, MIRT UAMS Little Rock, Arkanas
Regis Batille, Nantes, France
Meral Beksac, Ankara University, Turkey
Andrew Belch, Cross Cancer Institute, Canada
Mario Boccadoro, University of Torino
Michele Cavo, Bologna, Italy
Tony Child, United Kingdom
Ray Comenzo, Memorial-Sloan Kettering Cancer Center, New York
John Crowley, Cancer Research and Biostatistics, Seattle, Washington
William Dalton, H Lee Moffitt, Tampa, Florida
Faith Davies, Royal Marsden Hospital, London, England
Meletios Dimopoulos, Alexandra Hospital, Athens, Greece
Angela Dispenzieri, Mayo Clinic, Rochester, Minnesota
Brian Durie, Cedars-Sinai Outpatient Medical Center, Los Angeles, California
Theirry Facon, Centre Hospitalier Regional Universitaire de Lille, France
Dorotea Fantl, Buenos Aires, Argentina
Jean-Paul Fermand, Paris, France
Rafael Fonseca, Mayo Clinic Scottsdale, Scottsdale, Arizona
Gosta Gahrton, Karolinska Institutet, Stockholm , Sweden
Morie Gertz, Mayo Clinic
Hartmut Goldschmidt, Heidelberg, Germany
Philip Greipp, Mayo Clinic
Roman Hajek, Brno University, Brno, Czech Republic
Jean-Luc Harousseau, Institute de Biologie, Nantes, France
Kim Hawkins, Statistician, United Kingdom
Martin Hjorth, Data manager, Netherlands
Vania Hungria, Clinica San Germano, Sao Paolo, Brazil
Mohamad Hussein, The Cleveland Clinic, Cleveland, Ohio, USA
Peter Jacobs, South Africa
Mariana Juni, Fundaleu, Buenos Aires, Argentina
Douglas Joshua, Royal Prince Alfred Hospital, Sydney, Australia
Michael Katz, New York
Michio Kawano, Yamaguchi University, Ube, Japan
Shaji Kumar, Mayo Clinic
Robert Kyle, Mayo Clinic
Juan Lahuerta, Madrid, Spain
Henk Lokhorst, University Hospital, Utrecht, The Netherlands
Heinz Ludwig, Wilhelminenspital Der Stat Wien, Vienna
Jayesh Mehta, Northwestern University, Chicago
Giampaolo Merlini, University of Pavia, Pavia, Italy
Philippe Moreau, Nantes, France
Gareth Morgan, Royal Marsden Hospital, London
Antonio Palumbo, Cathedra Ematologia, Torino, Italy
Santiago Pavlovsky, Fundaleu, Buenos Aires, Argentina
Amara Nouel, Bolivar, Venezuela
Susie Novis, IMF, Los Angeles, California
Raymond Powles, Leukaemia & Myeloma, Wimbledon
Linda Pilarski, The University of Alberta, Edmonton Alberta, Canada
S Vincent Rajkumar, Mayo Clinic
Tony Reiman, Cross Cancer Institute, Canada
Paul Richardson, Dana Farber Cancer Institute, Boston, Massachusetts
Angelina Rodriquez Morales, Bonco MetroPolitano de Sangre, Caracas, Venezuela
Kazuyuki Shimizu, Nagoya City Midori General Hospital, Nagoya, Japan
David Siegel, Hackensack, Cancer Center, Hackensack, New Jersey
Guido Tricot, MIRT UAMS, Little Rock, Arkansas
Jesus San Miguel, University of Salamanca
Seema Singhal, Northwestern University
Pieter Sonneveld, Erasmus University Hospital, Rotterdam, The Netherlands
Keith Stewart, Mayo Clinic Scottsdale
Patrizia Tosi, Bologna, Italy
Ingemar Turesson, Malmo, Sweden
Ivan Van Riet, Brussels Vrija University
David Vesole, St Vincent's Comprehensive Cancer Center, New York
Donna Weber, MD Anderson, Houston, Texas
Jan Westin, University of Gothenberg, Sweden
Keith Wheatley, University of Birmingham, Edgbaston, Birmingham, UK
Brian Van Ness, University of Minnesota
Rights and permissions
About this article
Cite this article
Durie, B., Harousseau, JL., Miguel, J. et al. International uniform response criteria for multiple myeloma. Leukemia 20, 1467–1473 (2006). https://doi.org/10.1038/sj.leu.2404284
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404284
Keywords
This article is cited by
-
Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma – updated results after 18-year follow-up
Leukemia (2024)
-
The impact of social vulnerability index on survival following autologous stem cell transplant for multiple myeloma
Bone Marrow Transplantation (2024)
-
A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
Scientific Reports (2024)
-
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
Advances in Therapy (2024)
-
3D CNN-based Deep Learning Model-based Explanatory Prognostication in Patients with Multiple Myeloma using Whole-body MRI
Journal of Medical Systems (2024)